Overview

A Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Liver Impairment

Status:
Completed

Trial end date:
2021-06-01

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to evaluate the effect of liver impairment on the safety and pharmacokinetics (PK) of BMS-986263

Phase:

Phase 1

Details

Lead Sponsor:

Bristol-Myers Squibb